Cellino and Karis Bio Partners to Develop iPSC Therapy for Cardiovascular Disease in Asia-Pacific
Wednesday, April 16, 2025
Cellino has announced a new partnership with Karis Bio.
The collaboration marks Cellino’s entry into the Asia-Pacific region and aims to develop the first clinical-stage autologous induced pluripotent stem cell (iPSC)-derived therapy for peripheral artery disease (PAD) and coronary artery disease (CAD).
Karis Bio is developing an autologous iPSC-derived endothelial cell (iPSC-EC) therapy designed to promote the growth of new blood vessels in damaged or ischemic tissues. The therapy is intended to help restore blood flow and repair tissue in patients with cardiovascular disease. Unlike conventional treatments such as stents or bypass surgery, this approach is expected to reduce the risk of immune rejection, as it uses patient-specific cells.
The collaboration will make use of Cellino’s Nebula™ platform, an automated and closed biomanufacturing system that allows for the scalable and consistent production of autologous iPSCs. The technology is designed to operate at the point of care, supporting high-quality, contamination-free cell production.
The initial focus of the partnership will be on industrialising the production process in preparation for clinical use.
Combining Cellino’s automated manufacturing technology with Karis Bio’s expertise in cardiovascular regeneration is expected to support further advancements in regenerative medicine and strengthen efforts to bring personalised treatments to a global market.
The first human trials are already underway in South Korea, with plans to expand into Phase 2 trials in the United States through Karis Bio’s operations based in Atlanta.
This partnership reflects a shared goal of improving access to patient-specific cell therapies.
Source: cellinobio.com
